Частота возникновения и клинические характеристики головной боли при применении гранулоцитарного колониестимулирующего фактора у доноров костного мозга и пациентов с онкогематологическими заболеваниями

Цель исследования: определение частоты возникновения и клинических характеристик головной боли (ГБ) при применении гранулоцитарного колониестимулирующего фактора (Г-КСФ) для мобилизации стволовых клеток и лечения нейтропении у доноров и пациентов с онкогематологическими заболеваниями соответственно.
Материал и методы. В проспективное наблюдательное неконтролируемое исследование включено 39 участников — 20 доноров костного мозга и 19 пациентов с онкогематологическими заболеваниями. Оценивались частота развития и клинические характеристики ГБ на фоне подкожного введения Г-КСФ (филграстим) в дозировках 5–10 мкг/кг в течение 2–5 дней.
Результаты. ГБ чаще возникали у доноров в сравнении с пациентами, страдающими онкогематологическими заболеваниями (78,9% vs 35,0%; р = 0,006). Для групп доноров и пациентов с онкогематологическими заболеваниями значимых различий по времени возникновения ГБ относительно начала терапии Г-КСФ, ее длительности, интенсивности, характера и локализации выявлено не было. Пол, возраст, дозировка Г-КСФ и длительность его применения не были ассоциированы с развитием ГБ как в группе доноров, так и в группе пациентов с онкогематологическими заболеваниями.
Заключение. ГБ чаще возникает у доноров, нежели у пациентов с заболеванием онкогематологического профиля. Фенотип ГБ не является специфичным и требует дальнейшего уточнения семиотики.

1. Karagiannidis I., Salataj E., Said Abu Egal E., Beswick E.J. G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021;142:155479. https://doi.org/10.1016/j.cyto.2021.155479

2. Schmitt M., Hoffmann J.M., Lorenz K., Publicover A., Schmitt A., Nagler A. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111(2):178–186. https://doi.org/10.1111/vox.12397

3. Brockmann F., Kramer M., Bornhäuser M., Ehninger G., Hölig K. Efficacy and side effects of granulocyte collection in healthy donors. Transfus Med Hemother. 2013;40(4):258–264. https://doi.org/10.1159/000354093

4. Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4741199ef54f-4bcb-8798d0cc3095f783&t=%20(accessed%20Apr.%2009,%202021

5. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202

6. Moog R. Donor tolerance and results of stimulation with G-CSF alone or in combination with dexamethasone for the collection of granulocytes. J Clin Apher. 2004;19(3):115–118. https://doi.org/10.1002/jca.20013

7. Kröger N., Renges H., Sonnenberg S., Krüger W., Gutensohn K., Dielschneider T. et al. Stem cell mobilisation with 16 microg/ kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002;29(9):727–730. https://doi.org/10.1038/sj.bmt.1703509

8. Reik R.A., Noto T.A., Fernandez H.F. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997;12(1):10–13. https://doi.org/10.1002/(sici)1098-1101(1997)12:1<10::aid-jca3>3.0.co;2-d

9. Cesaro S., Marson P., Gazzola M.V., De Silvestro G., Destro R., Pillon M. et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica. 2002;87(8 Suppl):35–41.

10. Kröger N., Zander A.R. Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma. 2002;43(7):1391–1394. https://doi.org/10.1080/10428190290033323

11. Kröger N., Renges H., Krüger W., Gutensohn K., Löliger C., Carrero I. et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British journal of haematology. 2000:111(3);761–765.

12. Nakamura J., Nishi T.M., Yamashita S., Nakamura H., Sato K., Oda Y. et al. Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature. J Oncol Pharm Pract. 2020;26(7):1785–1790. https://doi.org/10.1177/1078155220910800

13. Gong Y., Hoover-Plow J. The plasminogen system in regulating stem cell mobilization. J Biomed Biotechnol. 2012;2012:437920. https://doi.org/10.1155/2012/437920

14. Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015

15. Noseda R., Copenhagen D., Burstein R. Current understanding of photophobia, visual networks and headaches. Cephalalgia. 2019;39(13):1623–1634. https://doi.org/10.1177/0333102418784750

16. Burstein R., Noseda R., Fulton A.B. Neurobiology of Photophobia. J Neuroophthalmol. 2019;39(1):94–102. https://doi.org/10.1097/WNO.0000000000000766

17. Young N.P., Elrashidi M.Y., McKie P.M., Ebbert J.O. Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia. 2018;38(12):1841–1848. https://doi.org/10.1177/0333102418758282

18. Singh N.N., Sahota P. Sleep-related headache and its management. Curr Treat Options Neurol. 2013;15(6):704–722. https://doi.org/10.1007/s11940-013-0258-1

19. Ahn A.H. Southern Headache Society supplement: the neurobiology of throbbing pain in migraine. Headache. 2012;52(Suppl.1):12–14. https://doi.org/10.1111/j.1526-4610.2012.02136.x

20. Meseeha M.G., Attia M. Throbbing headache is not always migraine; it can be serious. J Community Hosp Intern Med Perspect. 2016;6(5):32361. Published 2016 Oct 26. https://doi.org/10.3402/jchimp.v6.32361

21. Brusadelli T., Carnovale C., Gentili M., Borsadoli C., Speziali A., Perrone V. et al. Throbbing headache associated with enoxaparin administration: a case report, a review of pharmacovigilance databases for similar cases and possible mechanisms. J Clin Pharm Ther. 2015;40(3):342–344. https://doi.org/10.1111/jcpt.12257

22. Eyles J.L., Roberts A.W., Metcalf D., Wicks I.P. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2(9):500–510. https://doi.org/10.1038/ncprheum0291

23. Castellani S., D’Oria S., Diana A., Polizzi A.M., Di Gioia S., Mariggiò M.A. et al. G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis. Sci Rep. 2019;9(1):12937. Published 2019 Sep 10. https://doi.org/10.1038/s41598-019-49419-z

24. McColl S.R., Paquin R., Ménard C., Beaulieu A.D. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colonystimulating factor and tumor necrosis factor alpha. J Exp Med. 1992;176(2):593–598. https://doi.org/10.1084/jem.176.2.593

25. Rambe A.S., Sjahrir H., Machfoed M.H. Tumour Necrosis Factor-Α, Interleukin-1 and Interleukin-6 Serum Levels and Its Correlation with Pain Severity in Chronic Tension-Type Headache Patients: Analysing Effect of Dexketoprofen Administration. Open Access Maced J Med Sci. 2017;5(1):54–57. https://doi.org/10.3889/oamjms.2017.024

26. Koçer A., Memişoğullari R., Domaç F.M., Ilhan A., Koçer E., Okuyucu S. et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract. 2009;9(5):375–379. https://doi.org/10.1111/j.1533-2500.2009.00301.x

27. Conti P., D’Ovidio C., Conti C., Gallenga C.E., Lauritano D., Caraffa A. et al. Progression in migraine: Role of mast cells and proinflammatory and anti-inflammatory cytokines. Eur J Pharmacol. 2019;844:87–94. https://doi.org/10.1016/j.ejphar.2018.12.004

28. Han D. Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks. Ann Indian Acad Neurol. 2019;22(3):277–281. https://doi.org/10.4103/aian.AIAN_371_18

29. Messlinger K., Russo A.F. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661–1674. https://doi.org/10.1177/0333102418786261

30. Gong Q., Lin Y., Lu Z., Xiao Z. Microglia-Astrocyte Cross Talk through IL-18/IL-18R Signaling Modulates Migrainelike Behavior in Experimental Models of Migraine. Neuroscience. 2020;451:207–215. https://doi.org/10.1016/j.neuroscience.2020.10.019

31. He W., Long T., Pan Q., Zhang S., Zhang Y., Zhang D. et al. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. J Neuroinflammation. 2019;16(1):78. Published 2019 Apr 10. https://doi.org/10.1186/s12974-019-1459-7

32. Zhang X.C., Kainz V., Burstein R., Levy D. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain. 2011;152(1):140–149. https://doi.org/10.1016/j.pain.2010.10.002

33. Bowen E.J., Schmidt T.W., Firm C.S, Russo A.F, Durham P.L. Tumor necrosis factor-alpha stimulation of calcitonin generelated peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 2006;96(1):65–77. https://doi.org/10.1111/j.1471-4159.2005.03524.x

34. Yan J., Melemedjian O.K., Price T.J., Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012;8:6. Published 2012 Jan 24. https://doi.org/10.1186/1744-8069-8-6